Sign in

CIK 0001626971

  • Non-accelerated filer
  • Smaller reporting company

Corvus Pharmaceuticals, Inc.

Sign in to watch
Ticker
CRVS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464670809
Phone
+1 650-900-4520
Business address
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Derivatives Options or other derivatives
  2. 4 Open-market buy President and CEO bought 5,890 shares at an average $0.98 ($5,797)
  3. 4 Open-market buy President and CEO bought 15,000 shares at $1.64 ($24,534)
  4. 4 Open-market buy Chief Financial Officer bought 49,038 shares at an average $1.57 ($77,045)
  5. 4 Open-market buy President and CEO bought 30,000 shares at an average $1.49 ($44,600)
  6. 4 Open-market sale 10% owner sold 5,000,000 shares at an average $5.01 ($25,059,900)
  7. 4 Open-market sale Director sold 1,109,644 shares at $6.09 ($6,757,732)
  8. 4 Open-market sale Director sold 1,109,644 shares at $6.09 ($6,757,732)
  9. 3 Insider Initial Statement of Ownership
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Open-market buy President and CEO bought 10,000 shares at $1.93 ($19,254)

Page 5 of 13 · 252 filings